NQO1 sirna

NQO1 siRNA (Human)

Cat. Num. AAA8231363

• Gene Names: NQO1; DTD; QR1; DHQU; DIA4; NMOR1; NMORI
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: NQO1; NQO1 siRNA (Human); DIA4; NMOR1; NAD(P)H dehydrogenase [quinone] 1; Azoreductase; DT-diaphorase; DTD; Menadione reductase; NAD(P)H:quinone oxidoreductase 1; Phylloquinone reductase; Quinone reductase 1; QR1; NQO1 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: NQO1 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 274

• Applicable Applications for NQO1 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human NQO1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for NQO1 sirna

siRNA to inhibit NQO1 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 4505415
• NCBI GeneID: 1728
• NCBI Accession #: NP_000894.1
• NCBI GenBank Nucleotide #: NM_000903.2
• UniProt Accession #: P15559; Q86UK1; B2R5Y9; B4DNM7; B7ZAD1
• Molecular Weight: 26,365 Da
• NCBI Official Full Name: NAD(P)H dehydrogenase
• NCBI Official Synonym Full Names: NAD(P)H dehydrogenase, quinone 1
• NCBI Official Symbol: NQO1
• NCBI Official Synonym Symbols: DTD; QR1; DHQU; DIA4; NMOR1; NMORI
• NCBI Protein Information: NAD(P)H dehydrogenase [quinone] 1
• UniProt Protein Name: NAD(P)H dehydrogenase [quinone] 1
• Protein Family: NAD(P)H dehydrogenase
• UniProt Gene Name: NQO1
• UniProt Synonym Gene Names: DIA4; NMOR1; DTD; QR1
• UniProt Entry Name: NQO1_HUMAN

NCBI Description

This gene is a member of the NAD(P)H dehydrogenase (quinone) family and encodes a cytoplasmic 2-electron reductase. This FAD-binding protein forms homodimers and reduces quinones to hydroquinones. This protein's enzymatic activity prevents the one electron reduction of quinones that results in the production of radical species. Mutations in this gene have been associated with tardive dyskinesia (TD), an increased risk of hematotoxicity after exposure to benzene, and susceptibility to various forms of cancer. Altered expression of this protein has been seen in many tumors and is also associated with Alzheimer's disease (AD). Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jul 2008]

Uniprot Description

NQO1: a FAD-binding flavoprotein enzyme that that prevents the one electron reduction of quinones that results in the production of radical species. Involved in detoxification pathways as well as in biosynthetic processes such as the vitamin K-dependent gamma-carboxylation of glutamate residues in prothrombin synthesis. Mutations have been associated with tardive dyskinesia (TD), an increased risk of hematotoxicity after exposure to benzene, and susceptibility to various forms of cancer. The expression of NQO1 is increased in liver, colon and breast tumors and non-small cell lung cancer (NSCLC) compared with the normal tissues. Moreover, expression levels are also elevated in developing tumors, suggesting a role for NQ01 in the prevention of tumor development. A homozygous common missense variant (NQO1(*)2, rs1800566(T)), that disables NQO1 strongly predicts poor survival among two independent series of women with breast cancer. Studies on NQO1 knockout mice suggest that the lack of NQO1 enzymatic activity changes intracellular redox states resulting in a reduction in apoptosis, which in turn leads to myeloid hyperplasia of bone marrow. Altered expression is associated with Alzheimer's disease (AD). Inhibited by dicoumarol. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Oxidoreductase; EC 1.6.5.2

Chromosomal Location of Human Ortholog: 16q22.1

Cellular Component: cell soma; cytoplasm; cytosol

Molecular Function: identical protein binding; protein binding; NAD(P)H dehydrogenase (quinone) activity; cytochrome-b5 reductase activity; superoxide dismutase activity

Biological Process: response to ethanol; removal of superoxide radicals; xenobiotic metabolic process; response to toxin; positive regulation of neuron apoptosis; negative regulation of catalytic activity; regulation of amino acid metabolic process; nitric oxide biosynthetic process; response to nutrient; response to estradiol stimulus; synaptic transmission, cholinergic; aging